Introduction
============

The UK Multicentre Aneurysm Screening Study (MASS) investigated the effects of offering population screening for abdominal aortic aneurysm (AAA) to men aged 65--74 years. The results of this randomized trial[@b1], first reported at 4 years of follow-up in 2002, demonstrated that invitation to a one-time ultrasound screen and follow-up of identified aneurysms was effective in reducing AAA-related mortality. This clinical finding has been confirmed by longer-term follow-up from MASS[@b2]--[@b4], and reinforced by systematic reviews[@b5],[@b6] of evidence including other relevant trials. Based on the initial MASS results it was evident that screening in the context of the UK was likely to be cost-effective in the long-term[@b7]. This expectation was confirmed by a formal model that extrapolated from the 4-year follow-up data to estimate the long-term incremental cost per quality-adjusted life-year (QALY) for a screening programme of 65-year-old men, using the same screening methods and rescanning intervals for detected aneurysms as in MASS[@b8]. This estimated the incremental cost per QALY gained for those invited to screening compared with those not invited as £2970 (95 per cent uncertainty interval £2030 to £5430).

In the light of this clinical and cost-effectiveness evidence, and a positive review of all its criteria for a new screening programme, the UK National Screening Committee recommended that a National Health Service (NHS) AAA screening programme (NAAASP) be introduced. Phased implementation began in March 2009 with the aim to cover the whole of England by March 2013[@b9],[@b10]. Implementation is also under way in Wales, Scotland and Northern Ireland.

Early information from the NAAASP is now available, and it has been noted particularly that the prevalence of AAA at screening is considerably lower than that found in MASS (1·5 per cent compared with 4·9 per cent for MASS)[@b1],[@b10]. This paper re-estimates the cost-effectiveness of AAA screening as operationalized in England using the most up-to-date available data. The changes to the model reflect: a recalibration to take account of the 10-year follow-up of MASS, using individual patient data; incorporation of updated cost parameters reflecting the current costs of screening, rescans and procedures, including allowance for the introduction of elective endovascular aneurysm repair (EVAR); the use of more robust estimates of AAA growth and rupture rates based on recent meta-analyses[@b11],[@b12] of individual patient data; and key parameters observed in NAAASP to date (attendance rates, AAA prevalence and aortic size distribution).

Methods
=======

Original model
--------------

This re-estimation of the long-term cost-effectiveness of offering AAA screening used the cost-effectiveness model reported in 2007[@b8]. The underlying Markov model structure is shown in *Fig*. [1](#fig01){ref-type="fig"} and remained unchanged in this reanalysis. The two populations (those invited to AAA screening and those not invited) are modelled using 3-month cycles; each arrow in *Fig*. [1](#fig01){ref-type="fig"} represents a possible transition. The original model incorporated information from a range of sources to chart the detection, growth and treatment of AAAs over time for these populations, using the 4-year follow-up data from MASS as its prime source. It allowed estimation of 30-year costs and benefits of a programme offering a one-off screen to men aged 65 years with repeat scanning annually for aneurysms with a diameter of 3·0--4·4 cm (small AAA) and every 3 months for those with a diameter of 4·5--5·4 cm (medium AAA). Men with aneurysms over 5·4 cm (large AAA) would be referred for consideration for elective surgery. The model adopted an NHS perspective of costs.

![Markov model structure. AAA, abdominal aortic aneurysm. Reproduced from Kim *et al*.[@b8], with permission from *Journal of Medical Screening*](bjs0101-0976-f1){#fig01}

Revalidation and recalibration
------------------------------

The original model had been validated against the 4-year MASS data and shown to perform satisfactorily[@b13]. Using the longer 10-year follow-up data reported for MASS[@b3], a revalidation exercise was undertaken to assess how well the model predicted the longer-term observed data and to inform recalibration where necessary. Numbers of key events and cost-effectiveness (at 2008--2009 prices) observed in the trial were compared with results from the model.

To account for any emerging time trends in observed parameters, regression methods were used to derive time-dependent transition probabilities. Based on MASS, 10-year data probabilities were estimated for each 3-monthly cycle, determining transitions between states in the model. Recalibrations of parameter estimates for the rate of opportunistic detection and the rupture rate in large undetected AAAs were also carried out. These parameters cannot be estimated directly from MASS data; hence estimates were chosen to fit the observed data, with a focus on calibration to reflect best the incremental cost-effectiveness ratio (ICER) at 10 years based on observed follow-up. Rates were adjusted to minimize disparity in the modelled and observed differences between arms in key events. A previously published *Health Technology Assessment* monograph[@b14] deals with this process more comprehensively.

Re-estimation of unit costs
---------------------------

Following the model calibration, input parameters were updated to reflect contemporary costs. The unit cost estimates used in the original modelling related to the costs of screening as undertaken in MASS, and to contemporaneous estimates of the costs of elective and emergency procedures[@b7]. They were originally estimated at 2000--2001 prices, and in subsequent analyses were simply uplifted to account for general health service inflation. In this updated analysis, costs have been re-estimated and are presented at 2010--2011 price levels. Unit cost data for the screening itself were obtained from NAAASP[@b14]. Data from MASS[@b7], the EVAR-1 trial[@b15] and the National Vascular Database[@b16] were used to re-estimate the cost of surgical procedures. *Table* [1](#tbl1){ref-type="table"} shows the original aneurysm repair costs, together with the updated unit costs. A fuller account of this re-estimation has been published elsewhere[@b14].

###### 

Unit costs: original estimates from the Multicentre Aneurysm Screening Study, costs inflated to 2010--2011 prices, re-estimated unit costs, cost distributions applied in probabilistic sensitivity analysis, and source

  Cost component           Original cost 2000--2001 (£)   MASS cost inflated to 2010--2011 (£)   Re-estimated unit cost (£)   Distribution[\*](#tf1-1){ref-type="table-fn"}            Source
  ------------------------ ------------------------------ -------------------------------------- ---------------------------- -------------------------------------------------------- -------------------------
  Invitation to screen        1·31                            1·84                                   1·70                     Normal(1·7, 0·17)[†](#tf1-2){ref-type="table-fn"}        NAAASP
  Cost of first scan         19·08                          26·80                                   32·20                     Normal(32·2, 3·22)[†](#tf1-2){ref-type="table-fn"}       NAAASP
  Surveillance scan          46·04                          64·67                                   68·00                     Normal(68·0, 6·80)[†](#tf1-2){ref-type="table-fn"}       NAAASP
  Presurgical assessment    309·88                         435·25                                  435·25                      Normal(435·25, 87·05)[‡](#tf1-3){ref-type="table-fn"}   MASS
  Elective repair          6909·00                        9704·24                                12 806·21                    Normal(12 806, 2561)[‡](#tf1-3){ref-type="table-fn"}     Thompson *et al*.[@b14]
  Emergency repair         11 176·00                      15 697·59                              19 984·75                    Normal(19 985, 3996)[‡](#tf1-3){ref-type="table-fn"}     Thompson *et al*.[@b14]

Normal(μ, σ); standard deviation (σ)

10 per cent and

20 per cent of point estimate. MASS, Multicentre Aneurysm Screening Study; NAAASP, National Health Service abdominal aortic aneurysm screening programme.

Clinical data
-------------

The majority of probabilistic parameters that determine transitions between states in the Markov model have been updated using the 10-year follow-up data from MASS[@b3] (*Table* [2](#tbl2){ref-type="table"}). The postcalibration model was also updated to reflect available data from the current NAAASP. Data for attendance rates at screening (75 per cent *versus* 80 per cent in MASS), AAA prevalence (1·5 per cent *versus* 4·9 per cent in MASS) and the size distribution of aneurysms at initial screening (similar in NAAASP and MASS)[@b10] were incorporated (*Table* [2](#tbl2){ref-type="table"}). Sensitivity analysis around the 30-day surgical mortality rate was also conducted. The mortality rate after elective intervention for a screen-detected AAA observed in the NAAASP was lower (1·6 per cent *versus* 3·0 per cent in MASS), but based on few deaths, so it was deemed inappropriate to use it in the base case. Given the trend of an observed fall in the prevalence rate, a threshold analysis was also conducted to estimate the rate at which the modelling suggests the ICER would rise above £20 000 per QALY.

###### 

Clinical parameters: point estimate used in the model, distribution applied in probabilistic sensitivity analysis, and source

  --
  --

Growth and rupture rate estimates
---------------------------------

The postcalibration model also included improved estimates of aneurysm growth and rupture rates which were derived from the meta-analyses of individual patient data from 18 longitudinal studies of AAA screening surveillance programmes, undertaken as part of the RESCAN Collaboration[@b11]. The statistical methods used in these meta-analyses have been described elsewhere[@b11],[@b19], as has their incorporation into the modelling[@b14].

Implementation of the model
---------------------------

As before, the model was implemented in Microsoft® Excel (Microsoft, San Diego, California, USA), and a 30-year time horizon was adopted (essentially constituting a lifetime for the 65-year-old men considered). Long-term cost and life-years accrued in populations invited to, and not invited to, screening are the outcomes of interest, both discounted at 3·5 per cent per annum. As in previous versions of the modelling, QALYs are estimated by adjusting life-year estimates by EQ-5D™ (EuroQol Group, Rotterdam, The Netherlands) utility values for UK-relevant population age norms[@b20]. No further adjustment was made, based on the lack of differences in quality of life of those with an AAA[@b1]. Age-specific death rates from causes other than AAA were taken from UK national statistics[@b18].

The results are presented as an ICER of invitation to the screening programme compared with no invitation to screening. Probabilistic sensitivity analysis was undertaken to allow for parameter uncertainty, providing 1000 simulated ICER values. The distributions used for the uncertainty around the point estimate of each variable are detailed in *Tables* [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. For the updated time-dependent growth and rupture rates, a normally distributed multiplier (with mean 1 and based on a conservative approximation of the standard deviation from the mean of the pooled rates) was defined and sampled from, in order to increase or decrease all growth or rupture rates over time by a constant factor.

Results
=======

The revalidation process showed that the original model did not perform particularly well in predicting the observed MASS 10-year data. There were a number of discrepancies that together led to a substantial difference in the estimate of the 10-year ICER (*Table* [3](#tbl3){ref-type="table"}). Recalibration attempted to minimize the discrepancy in the estimated ICER. The recalibrated model predicted a 10-year ICER of £8900, compared with an ICER based on the 10-year observed data of £7600 per life-year.

###### 

Abdominal aortic aneurysm screening model: validation and recalibration of results using original cost estimates inflated to 2008--2009 prices for consistency

                                  Observed in MASS[\*](#tf3-1){ref-type="table-fn"}   Original model[†](#tf3-2){ref-type="table-fn"}   Model after recalibration to MASS 10-year follow-up data[‡](#tf3-3){ref-type="table-fn"}
  ------------------------------- --------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------------
  Control group                                                                                                                        
   Elective operations            226                                                 256                                              213
   Emergency operations           141                                                 140                                              168
   AAA deaths                     296                                                 305                                              385
   Non-AAA deaths                 10 185                                              10 139                                           10 148
   Life-years (mean)               7·509                                               7·291                                            7·282
   Mean cost (£)                  108                                                 118                                              124
  Invited group                                                                                                                        
   Elective operations            552                                                 607                                              539
   Emergency operations           62                                                  88                                               97
   AAA deaths                     155                                                 202                                              248
   Non-AAA deaths                 10 119                                              10 185                                           10 189
   Mean life-years                 7·523                                               7·297                                            7·293
   Mean cost (£)                  208                                                 233                                              225
  Difference between arms                                                                                                              
   Elective operations            326                                                 351                                              326
   Emergency operations           −79                                                 −52                                              −71
   AAA deaths                     −141                                                −103                                             −137
   Non-AAA deaths                 −66                                                 46                                               41
  Mean difference in life-years    0·013                                              0·006                                            0·011
  Mean difference in cost (£)     100                                                  115                                              101
  ICER (£)                                                                                                                             
   Life-years                     7600                                                18 000                                           8900
   QALYs                          9700                                                23 000                                           11 400

Key events and cost-effectiveness observed in Multicentre Aneurysm Screening Study (MASS) at 10-year follow-up.

Key events and cost-effectiveness results of modelling, using time-constant parameter estimates from MASS 10-year follow-up.

Key events and cost-effectiveness results of modelling, with time-dependent parameter estimates from MASS 10-year follow-up and after recalibration exercise. AAA, abdominal aortic aneurysm; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year (adjusted using population norms).

The updated 2010--2011 costs for screening and rescans were considerably higher than the 2000--2001 figures originally derived from MASS (*Table* [1](#tbl1){ref-type="table"}). Although this increase reflects general health service inflation, most of these specific costs have increased more rapidly. For example, the cost of elective repair now reflects the proportion of cases in which EVAR is used, leading to a cost that was 32 per cent higher than the inflated value of the original estimate. The estimate for an emergency repair was also 27 per cent higher.

The new estimates of life-years, costs and cost-effectiveness results, over a 30-year time horizon, for an AAA screening programme are shown in *Table* [4](#tbl4){ref-type="table"}. The ICER is now £5758 (95 per cent confidence interval £4285 to £7410) per life-year gained and £7370 (£5467 to £9443) per QALY gained.

###### 

Abdominal aortic aneurysm screening model: 30-year cost-effectiveness results at 2010--2011 prices for the current National Health Service abdominal aortic aneurysm screening programme

                                               Control group       Invited group   Difference
  -------------------------------------------- ------------------- --------------- ------------
  Life-years[†](#tf4-1){ref-type="table-fn"}   12·719              12·727          0·0084
  QALYs[](#tf4-1){ref-type="table-fn"}          9·921               9·928          0·0067
  Costs (£)                                    269                 316             47
  ICER (£)[](#tf4-2){ref-type="table-fn"}                                          
   Life-years                                  5758 (4285, 7410)                   
   QALYs                                       7370 (5467, 9443)                   

Values in parentheses are 95 per cent confidence intervals. Modelling after recalibration, incorporating Multicentre Aneurysm Screening Study (MASS) 10-year follow-up data, growth and rupture rates from meta-analysis of patient-level data, National Health Service abdominal aortic aneurysm screening programme (NAAASP) data on attendance, prevalence and abdominal aortic aneurysm size at initial screen and updated costs.

Life-years and costs discounted at 3·5 per cent.

Estimated from the mean of incremental cost-effectiveness ratios (ICERs) produced by 1000 probabilistic sensitivity analysis iterations. QALY, quality-adjusted life-year.

When presented on the cost-effectiveness plane (*Fig*. [2](#fig02){ref-type="fig"}), the 1000 iterations of the probabilistic sensitivity analysis show that, in all cases, the intervention provides additional QALYs but costs more. The figure demonstrates the low level of remaining uncertainty and that all estimates fall below the £20 000 threshold, as used by the National Institute for Health and Care Excellence (NICE)[@b21]. Furthermore, for any threshold value of a QALY over £10 000, there is at least a 99 per cent probability that the programme is cost-effective.

![National Health Service abdominal aortic aneurysm screening programme (NAAASP) cost-effectiveness estimates (30 years); 1000 probabilistic sensitivity analysis iterations. QALY, quality-adjusted life-year](bjs0101-0976-f2){#fig02}

The probabilistic sensitivity analysis incorporated the uncertainty around the postsurgical mortality observed in MASS; a one-way sensitivity analysis using the lower mortality rate observed in NAAASP, based on limited data, reduced the latter ICER by approximately £300. One-way sensitivity analysis suggests that the cost-effectiveness ratio would rise above the NICE £20 000 threshold at a prevalence of AAA in 65-year-old men of 0·35 per cent, compared with the observed 1·5 per cent.

Discussion
==========

To assess the cost-effectiveness of many interventions, particularly screening where the bulk of costs are upfront, but benefits are accrued over time, long-term modelling is essential. It is rare to be able to revisit a model originally constructed using short-term (4-year) trial evidence and compare modelled results with more robust mid-term (10-year) trial data. Such models may not, however, as here, predict well over the medium term. The efforts to recalibrate the model confirmed that the cost-effectiveness estimates are more sensitive to the modelled differences between arms in costs and outcomes (incremental costs and QALYs) than the absolute values in each arm. For that reason, the focus of calibration should be on these differences that drive the cost-effectiveness ratio. The revalidation exercise undertaken demonstrates that economists should be cautious in the use of models based on relatively short-term data[@b13], given that they may not extrapolate well to medium- or long-term outcomes.

These new analyses have not simply been updated to reflect longer-term trial data. Data from recent meta-analyses of aneurysm rupture and growth rates were used to estimate the growth and rupture rates over the long term. New unit cost estimates for the screening procedure and for AAA surgery that reflect current practice in the UK were incorporated. The new cost estimates demonstrate that, although simple adjustment using relevant price indices may be adequate for some unit costs, for some the procedure costs need to be re-estimated to reflect changes in the costs of particular resources, and changes in the process of care.

Most importantly from a policy perspective, the model incorporates key parameters from the first years of NAAASP: attendance, AAA prevalence and size distribution at first screen. The combined changes do mean that the estimated 30-year ICER of £7370 per QALY gained has increased; the original model estimated an ICER of £2970 per QALY gained[@b8]. The increase in the estimated ICER reflects the incorporation into the modelling of the much lower AAA prevalence found by NAAASP (1·5 per cent) compared with MASS (4·9 per cent). It also reflects, as might be expected, the fact that the cost of screening has increased since the first costing exercise was conducted in 2001. The costs of elective and emergency AAA repair have increased well above general health service inflation, in part due to the use of more expensive EVAR procedures.

Despite the increase in the estimated ICER, the new modelling demonstrates with confidence that AAA screening remains highly cost-effective, with an ICER well below the lower limit of NICE\'s acceptable cost-effectiveness range of £20 000--30 000 per QALY gained. The probabilistic sensitivity analysis suggests that, even at a level of £10 000 per QALY, the probability that NAAASP is cost-effective is 99 per cent, thus providing strong support for cost-effectiveness of the current screening programme in the UK.

Although early estimates of the cost-effectiveness of AAA screening predating the publication of results from randomized trials were very variable[@b22], and precise estimates of cost-effectiveness are necessarily country-specific, there is now a growing international consensus that one-off ultrasound screening in men at around age 65 years is cost-effective. This conclusion for the UK is paralleled by studies relating to Canada[@b23], Denmark[@b24],[@b25], The Netherlands[@b26], Norway[@b26], Northern Ireland[@b27] and Italy[@b28], with only one recent contrary estimate, also from Denmark[@b29].
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